Gene · 9097
Papers1,667
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 1,667
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| USP14 promotes epithelial-mesenchymal transition and functions as a multifaceted biomarker in lung adenocarcinoma. | Discov Oncol | 2026 | 41723339 | PubTator, text mining | PubMed |
| Structures of the 26S proteasome in complex with the Hsp70 co-chaperone Bag1 reveal a mechanism for direct substrate transfer. | Sci Adv | 2026 | 41719407 | PubTator, text mining | PubMed |
| Dysregulated post‑translational modifications in granulosa cells drive ovarian dysfunction and potential infertility applications (Review). | Int J Mol Med | 2026 | 41716015 | PubTator, text mining | PubMed |
| Mitochondria Pathway Signature Predicts Prognosis and Therapeutic Response and Identifies REXO2 as a Crucial Regulator in Breast Cancer. | Mediators Inflamm | 2026 | 41710263 | PubTator, text mining | PubMed |
| USP14-mediated inhibition of CDH11 ubiquitination propels IL-1β-induced chondrocyte injury. | Clin Rheumatol | 2026 | 41653235 | PubTator, text mining | PubMed |
| TMEM158-mediated TGF-β signaling pathway modulates the sensitivity of TP53-deficient osteosarcoma to USP14 inhibitors. | Mol Cell Biochem | 2026 | 41642468 | PubTator, text mining | PubMed |
| Spotlights on ubiquitin-specific proteases in lung cancer: from multifaceted pathophysiological mechanisms to potential therapeutic targets. | PeerJ | 2026 | 41635813 | PubTator, text mining | PubMed |
| CircKIAA1617 promotes stemness via USP14/PGRMC1-mediated autophagy and lipid metabolism reprogramming in ER-positive breast cancer. | Mol Cancer | 2026 | 41620724 | PubTator, text mining | PubMed |
| Targeting metabolic-epigenetic-immune axis in cancer: molecular mechanisms and therapeutic implications. | Signal Transduct Target Ther | 2026 | 41582215 | PubTator, text mining | PubMed |
| The Cullin3-Ring E3 ubiquitin ligase complex and USP14 regulate spastin-mediated microtubule severing and promotion of neurite outgrowth. | Neural Regen Res | 2026 | 40587243 | PubTator, text mining | PubMed |
| The ubiquitination-autophagy axis in cancer therapy resistance: mechanistic insights and therapeutic opportunities. | Front Pharmacol | 2025 | 41646943 | PubTator, text mining | PubMed |
| PSMD8 cooperates with USP14 to promote bladder cancer progression by inhibiting ferroptosis. | iScience | 2025 | 41403840 | PubTator, text mining | PubMed |
| Modulation of the tumor microenvironment by the ubiquitin-proteasome system in colorectal cancer. | J Transl Med | 2025 | 41361779 | PubTator, text mining | PubMed |
| Targeting ubiquitin-specific protease 14 reduces metastatic potential and metabolic activity in cervical cancer via direct modulation of monocarboxylate transporter-4. | J Transl Med | 2025 | 41327216 | PubTator, text mining | PubMed |
| USP14-mediated stabilization of ACTN1 maintains mesenchymal characteristics in glioblastoma. | Commun Biol | 2025 | 41291211 | PubTator, text mining | PubMed |
| The Ubiquitin-Proteasome System in Brain Disorders: Pathogenic Pathways, Post-Translational Tweaks, and Therapeutic Frontiers. | J Neuroimmune Pharmacol | 2025 | 41264052 | PubTator, text mining | PubMed |
| 18p Deletion Syndrome Associated with Type 1 Diabetes and Hashimoto's Thyroiditis: A Case Report on Autoimmune Disorders and Genetic Factors. | J Clin Res Pediatr Endocrinol | 2025 | 41194499 | PubTator, text mining | PubMed |
| PSMD11 facilitates immune escape by recruiting USP14 to modulate the deubiquitinating degradation of PD-L1 in non-small cell lung cancer. | J Thorac Dis | 2025 | 41158392 | PubTator, text mining | PubMed |
| Coelenterazine alleviates sepsis-associated acute kidney injury by inhibiting ferroptosis via the USP14-NCOA4 pathway. | Transl Androl Urol | 2025 | 41132357 | PubTator, text mining | PubMed |
| Molecular targeting of the deubiquitinase USP14 to circumvent cisplatin resistance in ovarian carcinoma and identification of novel inhibitors. | Cancer Drug Resist | 2025 | 41127338 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/9097/papers?page=3